Aprepitant for prevention of nausea and vomiting secondary to high-dose Cyclophosphamide administered to patients undergoing Autologous Peripheral Blood Stem Cells mobilization: A Phase II Trial

This is a phase II trial evaluating efficacy and safety of Aprepitant (AP) in combination with 5-HT3 antagonist and adjusted dose dexamethasone in patients receiving high-dose cyclophosphamide (CY) and filgrastim for stem cell mobilization. We used Simon’s optimal two-stage design constrained to few...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Abidi, Muneer H, Tageja, Nishant, Ayash, Lois, Abrams, Judith, Ratanatharathorn, Voravit, Al-Khadimi, Zaid, Lum, Lawrence, Cronin, Simon, Ventimiglia, Marie, Uberti, Joseph
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3594089/
https://ncbi.nlm.nih.gov/pubmed/22193771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-011-1341-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky